WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 01/11/21

In a positive start to 2021, the representative ETFs of Chinese companies rallied by a wide margin over with their respective U.S. counterparts. The outperformance came despite the dark cloud of investment bans on Alibaba and Tencent, as well as usage prohibition of certain Chine...

Jacobio raised $174 million in a Hong Kong IPO to develop its portfolio of 12 novel drugs. WuXi Biologics will add more CDMO capacity by spending $183 million to acquire a Bayer facility in Germany. CASI Pharma announced its partnered CD19 CAR-T product was granted Breakthrough De...

Wuxi Biologics (WXXWY) is acquiring a drug substance facility from Bayer (BAYZF) to ramp up its global supply network of COVID-19 vaccines and other biologics.As part of the agreement, the two companies also plan to enter a long-term sublease agreement and a transition service contr...

Arcus Biosciences ([[RCUS]] +2.6%) has expanded its existing strategic relationship with WuXi Biologics ([[WXXWY]] -65.6%) to discover anti-CD39 antibodies using the latter’s proprietary technology. It is the fourth antibody development program for which the two firms have collabo...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors or multiple myeloma. LianBio, a P...

In the US, a comparison of the MSCI USA and MSCI USA ESG indexes shows that ESG did not increase performance with the former returning 140% and the latter 130% since 2013. It is important to note that the ESG criteria MSCI uses for its China ESG indexes are the same criteria MSCI uses...

AC Immune (ACIU) and WuXi Biologics (WXXWY) plan to accelerate advancement of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications. This next phase of the strategic partnership between the companies builds on the know-how of ACIU's drug discovery and develo...

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines PR Newswire SHANGHAI, Oct. 10, 2020 SHANGHAI , Oct. 10, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceutical c...

Shrugging off COVID-19-related disruptions, WuXi Biologics ( OTCPK:WXXWY ) delivered a 21.0% increase in H1 revenue (RMB1,944.1M). Gross profit surged 17.3% to RMB787.3M. More news on: Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Cayman) Inc., Healthcare stocks news, Earnings news an...